Moreover, focus must shift towards slowly eradicating cycling tumor-initiating cells that are resistant to cytotoxic drugs and inhibitors, such as those expressing SOX2+ or high H3K27 methylation and EZH2 expression, and can eventually give rise to recurrent tumors recalcitrant to treatment. The gene discussed is EZH2; the disease is neoplasm.